Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gatifloxacin.

C M Perry1, J A Barman Balfour, H M Lamb

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|November 7, 1999
PubMed
Summary
This summary is machine-generated.

Gatifloxacin, a new fluoroquinolone antibiotic, shows broad-spectrum efficacy against Gram-positive and anaerobic bacteria. Clinical trials demonstrate high cure rates for various infections, with good tolerability and no phototoxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

131I tositumomab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Trastuzumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Recombinant Mammalian Cell-Derived Somatropin: A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Wasting Associated with HIV Infection.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Interferon-alpha-n1: a review of its pharmacological properties and therapeutic efficacy in the management of chronic viral hepatitis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Cladribine: a review of its use in multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Gatifloxacin is an extended-spectrum fluoroquinolone antibiotic.
  • It offers improved coverage against Gram-positive and anaerobic bacteria compared to older agents like ciprofloxacin.
  • It exhibits good activity against Enterobacteriaceae.

Purpose of the Study:

  • To evaluate the clinical efficacy and tolerability of gatifloxacin.
  • To compare gatifloxacin with other antibiotics in treating various infections.

Main Methods:

  • Comparative clinical trials were conducted in patients with lower respiratory tract, urinary tract, skin and soft tissue, and gonococcal infections.
  • Oral gatifloxacin (400 mg/day for 7-14 days) was administered.
  • Efficacy was assessed by clinical cure rates and bacterial eradication.

Related Experiment Videos

Main Results:

  • Clinical cure rates exceeding 89% were achieved with oral gatifloxacin.
  • Gatifloxacin demonstrated significantly higher cure rates than cefuroxime axetil in acute exacerbations of chronic bronchitis.
  • Efficacy was comparable to clarithromycin, levofloxacin, and ceftriaxone in community-acquired pneumonia and skin/soft tissue infections.
  • Similar clinical cure and bacterial eradication rates were observed in urinary tract infections compared to ciprofloxacin.

Conclusions:

  • Gatifloxacin is an effective antibiotic for treating a range of infections.
  • It is generally well-tolerated, with common side effects including nausea, diarrhea, headache, and dizziness.
  • Gatifloxacin does not appear to cause phototoxic effects.